Ligand Pharmaceuticals (NASDAQ:LGND) just reported results for the first quarter of 2024.
- Ligand Pharmaceuticals reported earnings per share of $3.84. This was above the analyst estimate for EPS of 78 cents.
- The company reported revenue of $30.98 million.
- This was 10.95% better than the analyst estimate for revenue of $27.92 million.